Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas

Journal of Pathology

Volumn 225, Issue 3, 2011, Pages 344-352

  Boult, Jessica K R ^a   Walker Samuel, Simon ^a   Jamin, Yann ^a   Leiper, James M ^b   Whitley, Guy St J ^c   Robinson, Simon P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

angiogenesis; biomarkers; dimethylarginine dimethylaminohydrolase; magnetic resonance imaging; nitric oxide; xenograft models

Indexed keywords

CD31 ANTIGEN; DIMETHYLARGININASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 1; HOE 33342; N(G),N(G) DIMETHYLARGININE; PIMONIDAZOLE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENDOTHELIUM; ENZYME ACTIVITY; FEMALE; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; GLIOMA; HISTOLOGY; HYPOXIA; METABOLISM; MOUSE; MUTANT; NECROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

AMIDOHYDROLASES; ANIMALS; ARGININE; CATALYTIC DOMAIN; FEMALE; GLIOMA; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; MUTATION; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; RATS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80054719123     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2904     Document Type: Article

References (42)

1. Folkman J,. Tumor angiogenesis. Adv Cancer Res 1985; 43: 175-203.
2. Ferrara N,. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527-543. (Pubitemid 29426311)
3. Fukumura D, Kashiwagi S, Jain R,. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6: 521-534. (Pubitemid 43980541)
4. Chinje E, Stratford I,. Role of nitric oxide in growth of solid tumours: a balancing act. Essays Biochem 1997; 32: 61-72. (Pubitemid 127470401)
5. Miller T, Isenberg J, Roberts D,. Molecular regulation of tumor angiogenesis and perfusion via redox signaling. Chem Rev 2009; 109: 3099-3124.
6. Chin K, Kurashima Y, Ogura T, et al., Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. Oncogene 1997; 15: 437-442. (Pubitemid 27370993)
7. Dulak J, Jõzkowicz A, Dembinska-Kiec A, et al., Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 659-666. (Pubitemid 30151678)
8. Rees D, Palmer R, Schulz R, et al., Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990; 101: 746-752. (Pubitemid 20357206)
9. Ogawa T, Kimoto M, Sasaoka K,. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989; 264: 10205-10209. (Pubitemid 19159295)
10. Kostourou V, Robinson S, Cartwright J, et al., Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer 2002; 87: 673-680.
11. Tran C, Fox M, Vallance P, et al., Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics 2000; 68: 101-105.
12. Smith C, Birdsey G, Anthony S, et al., Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun 2003; 308: 984-989. (Pubitemid 36976555)
13. Wojciak-Stothard B, Torondel B, Tsang L, et al., The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J Cell Sci 2007; 120: 929-942. (Pubitemid 46638508)
14. Konishi H, Sydow K, Cooke J,. Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury. J Am Coll Cardiol 2007; 49: 1099-1105. (Pubitemid 46349507)
15. Jacobi J, Sydow K, von Degenfeld G, et al., Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 2005; 111: 1431-1438. (Pubitemid 40396810)
16. Fiedler L, Bachetti T, Leiper J, et al., The ADMA/DDAH pathway regulates VEGF-mediated angiogenesis. Arterioscler Thromb Vasc Biol 2009; 29: 2117-2124.
17. Jang J, Ho H, Kwan H, et al., Angiogenesis is impaired by hypercholesterolemia: role of asymmetric dimethylarginine. Circulation 2000; 102: 1414-1419.
18. Ito A, Tsao P, Adimoolam S, et al., Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-3095. (Pubitemid 29289071)
19. Breckenridge R, Kelly P, Nandi M, et al., A role for dimethylarginine dimethylaminohydrolase 1 (DDAH1) in mammalian development. Int J Dev Biol 2010; 54: 215-220.
20. Leiper J, Nandi M, Torondel B, et al., Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007; 13: 198-203.
21. Morishita T, Tsutsui M, Shimokawa H, et al., Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Natl Acad Sci USA 2005; 102: 10616-10621. (Pubitemid 41061603)
22. Galkin A, Kulakova L, Sarikaya E, et al., Structural insight into arginine degradation by arginine deiminase, an antibacterial and parasite drug target. J Biol Chem 2004; 279: 14001-14008. (Pubitemid 38468934)
23. Leiper J, Murray-Rust J, McDonald N, et al., S-Nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 2002; 99: 13527-13532. (Pubitemid 35215415)
24. Wojciak-Stothard B, Torondel B, Zhao L, et al., Modulation of Rac1 activity by ADMA/DDAH regulates pulmonary endothelial barrier function. Mol Biol Cell 2009; 20: 33-42.
25. Workman P, Aboagye E, Balkwill F, et al., Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102: 1555-1577.
26. MacAllister R, Parry H, Kimoto M, et al., Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533-1540. (Pubitemid 27019525)
27. Walker-Samuel S, Orton M, McPhail L, et al., Robust estimation of the apparent diffusion coefficient (ADC) in heterogeneous solid tumors. Magn Reson Med 2009; 62: 420-429.
28. McSheehy P, Weidensteiner C, Cannet C, et al., Quantified tumor T1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability. Clin Cancer Res 2010; 16: 212-225.
29. Weidensteiner C, Rausch M, McSheehy P, et al., Quantitative dynamic contrast-enhanced MRI in tumor-bearing rats and mice with inversion recovery TrueFISP and two contrast agents at 4.7 T. J Magn Reson Imaging 2006; 24: 646-656. (Pubitemid 44320569)
30. Jakobsen I, Lyng H, Kaalhus O, et al., MRI of human tumor xenografts in vivo: proton relaxation times and extracellular tumor volume. Magn Reson Imaging 1995; 13: 693-700.
31. Walker-Samuel S, Leach M, Collins D,. Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis. Phys Med Biol 2006; 51: 3593-3602. (Pubitemid 44026420)
32. Kostourou V, Troy H, Murray J, et al., Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo. Neoplasia 2004; 6: 401-411. (Pubitemid 38924855)
33. Howe FA, McPhail LD, Griffiths JR, et al., Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model. Int J Radiat Oncol Biol Phys 2008; 71: 1470-1476.
34. Nagai T, Tanaka M, Tsuneyoshi Y, et al., Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor-β. Cancer Immunol Immunother 2009; 58: 1577-1586.
35. Kostourou V,. The role of nitric oxide and dimethylarginine dimethylaminohyrdrolase in tumour growth and angiogenesis. PhD Thesis. Department of Biochemistry and Immunology, St George's Hospital Medical School, University of London: London; 295.
36. Hasegawa K, Wakino S, Tanaka T, et al., Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Sp1 transcription factor in endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26: 1488-1494. (Pubitemid 44288973)
37. Hecker M, Mitchell J, Harris H, et al., Endothelial cells metabolize NG-monomethyl- L -arginine to L -citrulline and subsequently to L -arginine. Biochem Biophys Res Commun 1990; 167: 1037-1043. (Pubitemid 20113285)
38. Pope AJ, Karrupiah K, Kearns PN, et al., Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production. J Biol Chem 2009; 284: 35338-35347.
39. Kimoto M, Whitley G, Tsuji H, et al., Detection of NG,NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem 1995; 117: 237-238.
40. Kostourou V, Robinson S, Whitley G, et al., Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res 2003; 63: 4960-4966. (Pubitemid 37022632)
41. O'Connor J, Carano R, Clamp A, et al., Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 2009; 15: 6674-6682.
42. Tokuo H, Yunoue S, Feng L, et al., Phosphorylation of neurofibromin by cAMP-dependent protein kinase is regulated via a cellular association of N(G),N(G)-dimethylarginine dimethylaminohydrolase. FEBS Lett 2001; 494: 48-53. (Pubitemid 32289370)